Anti-spasmogenic effects of bencianol (ZY15051) on human cerebral arteries in vitro.
Experiments were performed to assess the ability of bencianol (ZY15051) to reverse contractions of human basilar arteries in vitro that were induced by a wide range of substances implicated in the aetiology of migraine and cerebral arterial spasm. Bencianol caused a dose-related (1-100 micrograms ml-1) reversal of contractions induced by 5-hydroxytryptamine, noradrenaline, angiotensin II, prostaglandin F2 alpha, and U-46619 (a thromboxane-A2 mimetic). Bencianol was more effective against contractions induced by EC50 compared to maximal concentrations of each agent, and was least effective against the thromboxane-A2 mimetic, U-46619. In addition, contractions induced by thromboxane-A2-like substances generated from guinea-pig lungs were also reversed by bencianol but only at the highest concentration used (100 micrograms ml-1). The relevance of this action of bencianol to migraine and cerebral arterial spasm is discussed.
D001488:Basilar Artery / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005419:Flavonoids / Q000627:therapeutic use*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008881:Migraine Disorders / Q000188:drug therapy*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
D005419:Flavonoids; D014665:Vasodilator Agents; C047756:bencianol